The market share for DaVita and Fresenius grew from 59.1% to 77.1% from 2005 to 2019, and 32.5% of people lived in hospital ...

Key findings of subgroup analyses included an observed increased psoriasis risk in patients without atopic comorbidities (HR 1.42, 95% CI 1.06-1.89) and those with pretreatment immunoglobulin E (IgE) ...